id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1976-N-0519-0008,FDA,FDA-1976-N-0519,"Acknowledgement Letter from FDA/DDM to Foley & Lardner, LLP",Other,Acknowledgement Letter/Receipt,2005-12-09T05:00:00Z,2005,12,,,2016-02-23T21:34:28Z,,0,0,090000648053bd53
FDA-1976-N-0519-0007,FDA,FDA-1976-N-0519,"Acknowledgement Letter from FDA/DDM to Foley & Lardner, LLP",Other,Acknowledgement Letter/Receipt,2005-12-09T05:00:00Z,2005,12,,,2016-03-08T16:10:22Z,,0,0,090000648053bd52
FDA-1976-N-0519-0006,FDA,FDA-1976-N-0519,Memorandum from FDA/ OC to FDA/DDM,Other,Memorandum,2005-11-02T05:00:00Z,2005,11,,,2016-03-08T16:28:44Z,,0,0,090000648053bd3e
FDA-1976-N-0519-0005,FDA,FDA-1976-N-0519,Memorandum of Telephone Conversation Between Barnes & Thornburg LLP and FDA/CDER,Other,Memorandum,2005-10-05T04:00:00Z,2005,10,,,2016-02-23T21:15:35Z,,0,0,090000648053bd35
FDA-1976-N-0519-0004,FDA,FDA-1976-N-0519,Memorandum of Telephone Conversation Between Barnes & Thornburg LLP and FDA/CDER,Other,Memorandum,2005-10-05T04:00:00Z,2005,10,,,2016-03-07T19:01:12Z,,0,0,090000648053bd34
FDA-1976-N-0519-0003,FDA,FDA-1976-N-0519,"Notice of Proposed Rulemaking  re Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph for Combination Drug Products",Proposed Rule,Notice of Proposed Rulemaking (NPRM),2005-07-15T04:00:00Z,2005,7,2005-07-12T04:00:00Z,2005-11-11T04:59:59Z,2018-12-20T02:03:42Z,,0,0,090000648053bd30